TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29621042

Group type: EXPERIMENTAL
Intervention: Ocriplasmin 0.125 mg injected once
Number of subjects: 10
Study: 26795064

Group type: EXPERIMENTAL
Intervention: Frontline Tri-Act(®) topical treatment
Number of subjects: 16

Group type: COMPARATOR
Intervention: Untreated control
Number of subjects: 16
Study: 25008392

Group type: EXPERIMENTAL
Intervention: Fulranumab 10 mg
Number of subjects: 77

Group type: COMPARATOR
Intervention: Fulranumab (1, 3, or 10 mg)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study: 22825089

Group type: EXPERIMENTAL
Intervention: Exercise initiated at 13 weeks (group A)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exercise initiated at 20 weeks (group B)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (group C)
Number of subjects: 0
Study: 20032964

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) for 6 months
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no MMF)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 40
Study: 19210877

Group type: EXPERIMENTAL
Intervention: Iloprost therapy (5-day infusion)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study: 16164452

Group type: EXPERIMENTAL
Intervention: Low-dose, double-blind, placebo-controlled food challenge (DBPCFC) with peanut
Number of subjects: 40
Study: 10901785

Group type: EXPERIMENTAL
Intervention: Mail survey with follow-up letter
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Mail survey without follow-up letter
Number of subjects: 400

Group type: COMPARATOR
Intervention: Telephone interview
Number of subjects: 400

Group type: COMPARATOR
Intervention: Face to face interview
Number of subjects: 400

Group type: COMPARATOR
Intervention: Home interview
Number of subjects: 400
Study: 8708947

Group type: EXPERIMENTAL
Intervention: Chlorhexidine (CHX) acetate chewing gum (5.0 mg CHX acetate/piece)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Sorbitol-containing chewing gum (1.0 g sorbitol/piece)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Xylitol-containing chewing gum (0.8 g xylitol/piece)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Regular plaque control routines
Number of subjects: 14

Group type: COMPARATOR
Intervention: Xylitol-containing chewing gum
Number of subjects: 14
Study: 2060556

Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Digitoxin
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 30389590

Group type: EXPERIMENTAL
Intervention: Recovery Position (RP) and checking breathing regularly
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Recovery Position (RP) while re‐evaluating breathing every minute
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Head‐tilt‐chin‐lift technique
Number of subjects: 192
Study: 27756583

Group type: EXPERIMENTAL
Intervention: NORCAP (vinorelbine/capecitabine)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: GEMPAC (gemcitabine/paclitaxel)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: GEMDOC (gemcitabine/docetaxel)
Number of subjects: 149
Study: 23888342

Group type: EXPERIMENTAL
Intervention: Testosterone replacement therapy with physiotherapy (TRT+PT) for 6 months
Number of subjects: 18

Group type: COMPARATOR
Intervention: Testosterone replacement therapy alone (TRT) for 6 months
Number of subjects: 18
Study: 21482968

Group type: EXPERIMENTAL
Intervention: Bivalirudin monotherapy (n=1800)
Number of subjects: 3602

Group type: COMPARATOR
Intervention: Heparin plus glycoprotein IIb/IIIa inhibitor (GPI) (n=1802)
Number of subjects: 3602

Group type: EXPERIMENTAL
Intervention: Drug-eluting stents
Number of subjects: 3602

Group type: EXPERIMENTAL
Intervention: Bare metal stents
Number of subjects: 3602

Group type: EXPERIMENTAL
Intervention: Overall stent thrombosis
Number of subjects: 3602
Study: 19071236

Group type: EXPERIMENTAL
Intervention: Patients with OI
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Patients with OI with haploinsufficiency mutations
Number of subjects: 64
Study: 17631392

Group type: EXPERIMENTAL
Intervention: etoricoxib 30 mg q.d.
Number of subjects: 548

Group type: EXPERIMENTAL
Intervention: ibuprofen 2400 mg (800 mg t.i.d.)
Number of subjects: 548

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 548
Study: 15178376

Group type: EXPERIMENTAL
Intervention: VOE tasks with test trials only
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control results
Number of subjects: 0
Study: 11732707

Group type: EXPERIMENTAL
Intervention: Ketamine (noncompetitive NMDA receptor antagonist)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Unmedicated schizophrenic group
Number of subjects: 28

Group type: COMPARATOR
Intervention: Medicated schizophrenic group
Number of subjects: 28

Group type: COMPARATOR
Intervention: Normal volunteers
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Schizophrenic group (task vs. condition comparison)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Normal group (task vs. condition comparison)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Schizophrenic group (task and control conditions)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Normal group (task and control conditions)
Number of subjects: 28
Study: 10874361

Group type: EXPERIMENTAL
Intervention: Nimodipine (120 mg/day for 28 days)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 8580704

Group type: EXPERIMENTAL
Intervention: Measurement of unbound L-tryptophan concentrations using reverse-phase HPLC with fluorescence detection
Number of subjects: 9
Study: 2526365

Group type: EXPERIMENTAL
Intervention: Inpatient treatment
Number of subjects: 456

Group type: COMPARATOR
Intervention: Outpatient treatment
Number of subjects: 456

Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 456

Group type: EXPERIMENTAL
Intervention: Increased trunk extension strength
Number of subjects: 456

Group type: EXPERIMENTAL
Intervention: Improved physical fitness
Number of subjects: 456

Group type: EXPERIMENTAL
Intervention: Increase of lumbar and hip mobility
Number of subjects: 456
Study: 412613

Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate
Number of subjects: 0
Study: 31529159

Group type: EXPERIMENTAL
Intervention: Three or more adverse events
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Permanent OAA stoppage
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no adverse events or medication stoppage)
Number of subjects: 60
Study: 29168741

Group type: EXPERIMENTAL
Intervention: Tyrosine 100 mg/kg
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Tyrosine 150 mg/kg
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Tyrosine 200 mg/kg
Number of subjects: 17

Group type: COMPARATOR
Intervention: Tyrosine 150 mg/kg (young adults)
Number of subjects: 17
Study: 26023914

Group type: EXPERIMENTAL
Intervention: Moderate physical activity intervention (150 additional minutes of exercise per week)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Extensive physical activity intervention (300 additional minutes of exercise per week)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 129
Study: 23449826

Group type: EXPERIMENTAL
Intervention: Sorafenib/bevacizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sorafenib monotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bevacizumab monotherapy
Number of subjects: 0
Study: 22066891

Group type: EXPERIMENTAL
Intervention: NOMAC/E2 (2.5 mg/1.5 mg) in a 24/4-day regimen (n=60)
Number of subjects: 121

Group type: COMPARATOR
Intervention: LNG/EE (150 μg/30 μg) in a 21/7-day regimen (n=61)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: NOMAC/E2
Number of subjects: 121

Group type: COMPARATOR
Intervention: LNG/EE
Number of subjects: 121
Study: 18046544

Group type: EXPERIMENTAL
Intervention: Propranolol (beta-adrenergic blockade)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reboxetine (selective NE reuptake inhibitor)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nadolol (peripheral beta-adrenergic antagonist)
Number of subjects: 0
Study: 16141462

Group type: EXPERIMENTAL
Intervention: Dual RAAS blockade (losartan and lisinopril)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Proteinuric patients
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Combined antiproteinuric treatment
Number of subjects: 6
Study: 15576063

Group type: EXPERIMENTAL
Intervention: Antipanic medication
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy
Number of subjects: 25

Group type: COMPARATOR
Intervention: Normal comparison subjects
Number of subjects: 25
Study: 11243292

Group type: EXPERIMENTAL
Intervention: Ampicillin/sulbactam (Group 1)
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Cefotetan (Group 2)
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Ampicillin (Group 3)
Number of subjects: 301

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 301
Study: 9349065

Group type: EXPERIMENTAL
Intervention: Pethidine 25 mg with adrenaline 50 micrograms (adrenaline group, n = 20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Pethidine 25 mg without adrenaline (plain group, n = 18)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Pethidine 25 mg with adrenaline 50 micrograms (adrenaline group)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Pethidine 25 mg without adrenaline (plain group)
Number of subjects: 40
Study: 8462415

Group type: EXPERIMENTAL
Intervention: 30% nitrous oxide in oxygen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 40% nitrous oxide in oxygen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nitrous oxide (both concentrations)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (oxygen)
Number of subjects: 0
Study: 3950827

Group type: EXPERIMENTAL
Intervention: Fluorescent green lamps (Sylvania F20T12/G)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Special blue lamps (Westinghouse F20T12/BB)
Number of subjects: 2
Study: 30220508

Group type: EXPERIMENTAL
Intervention: SC (shear test 24h after bonding)
Number of subjects: 60

Group type: COMPARATOR
Intervention: μTC (microtensile test 24h after bonding)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: μTF (microtensile test after mechanical fatigue)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: μTT (microtensile test after thermocycling)
Number of subjects: 60
Study: 27392388

Group type: EXPERIMENTAL
Intervention: Steroid-eluting ethmoidal stent (SEES)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Endoscopic ethmoidectomy (EE)
Number of subjects: 70
Study: 24682707

Group type: EXPERIMENTAL
Intervention: Interview skills curriculum (ISC), a manualized 12-week group-delivered intervention.
Number of subjects: 28

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 28
Study: 24349171

Group type: EXPERIMENTAL
Intervention: Music classes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visual arts classes
Number of subjects: 0

Group type: COMPARATOR
Intervention: No treatment control
Number of subjects: 0
Study: 19854713

Group type: EXPERIMENTAL
Intervention: 200 mg oral DHEA
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 19036149

Group type: EXPERIMENTAL
Intervention: Nurse clinic care
Number of subjects: 126

Group type: COMPARATOR
Intervention: Home care
Number of subjects: 126
Study: 17237853

Group type: EXPERIMENTAL
Intervention: Induction 2 cycles paclitaxel (175 mg/m2) and carboplatin (AUC 6) followed by concomitant paclitaxel (45 mg/m2) and carboplatin (AUC 2) weekly with radiotherapy (Group A)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Concomitant carboplatin, paclitaxel (same doses as in Group A) and radiotherapy (Group B)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Only radiotherapy to a total dose of 60 Gy in conventional fractionation (Group C)
Number of subjects: 60
Study: 14616430

Group type: EXPERIMENTAL
Intervention: St John's wort extract (300 mg, twice daily)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: St John's wort extract (300 mg, three times daily)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Low-dose oral contraceptive alone (control)
Number of subjects: 18
Study: 10749463

Group type: EXPERIMENTAL
Intervention: Ceftriaxone for 4 days (4 injections)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Ceftriaxone for 7 days
Number of subjects: 100
Study: 8932983

Group type: EXPERIMENTAL
Intervention: recombinant human interleukin‐6 (rhIL‐6) at doses of 1, 3 or 10 micrograms/kg/day for 7 consecutive days
Number of subjects: 12

Group type: COMPARATOR
Intervention: cyclophosphamide/G‐CSF
Number of subjects: 12
Study: 1573785

Group type: EXPERIMENTAL
Intervention: SPG group (radiotherapy + SPG)
Number of subjects: 292

Group type: COMPARATOR
Intervention: Control group (radiotherapy only)
Number of subjects: 292
Study: 3931145

Group type: EXPERIMENTAL
Intervention: Alprazolam 0.5 mg b.i.d. for 7 days
Number of subjects: 18

Group type: COMPARATOR
Intervention: Diazepam 5 mg b.i.d. for 7 days
Number of subjects: 18
Study: 30997619

Group type: COMPARATOR
Intervention: Medical Weight Loss (MWL)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Adjustable Gastric Banding (AGB)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Roux-en-Y Gastric Bypass (RYGB)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: AGB
Number of subjects: 15
Study: 28667715

Group type: EXPERIMENTAL
Intervention: Family-centered care intervention using an audio-video tool on personal hygiene, hand washing, danger signs recognition, and feeding of sick neonate.
Number of subjects: 295

Group type: COMPARATOR
Intervention: Routine care by nurses and doctors (Control group).
Number of subjects: 295
Study: 25046337

Group type: EXPERIMENTAL
Intervention: Omalizumab 75 mg
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Omalizumab 150 mg
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Omalizumab 300 mg
Number of subjects: 319

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 319
Study: 24039365

Group type: COMPARATOR
Intervention: PPI (lansoprazole 30 mg/d orally)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: rebamipide (300 mg orally, three times a day)
Number of subjects: 90
Study: 21768463

Group type: EXPERIMENTAL
Intervention: Erlotinib plus tivantinib (ET) - erlotinib (150 mg daily) and tivantinib (360 mg twice daily)
Number of subjects: 167

Group type: COMPARATOR
Intervention: Erlotinib plus placebo (EP) - erlotinib (150 mg daily) and placebo
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Erlotinib plus tivantinib (ET)
Number of subjects: 167

Group type: COMPARATOR
Intervention: Erlotinib plus placebo (EP)
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Erlotinib plus tivantinib (ET) for patients with KRAS mutations
Number of subjects: 167

Group type: COMPARATOR
Intervention: Erlotinib plus placebo (EP) with crossover to ET
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Erlotinib plus tivantinib (ET) and Erlotinib plus placebo (EP)
Number of subjects: 167
Study: 19805683

Group type: EXPERIMENTAL
Intervention: Single oral dose casopitant (150 mg PO on day 1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 3-day oral casopitant (150 mg PO on day 1 plus 50 mg PO on days 2 to 3)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 3-day IV/oral casopitant (90 mg IV on day 1 plus 50 mg PO on days 2 to 3)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 0
Study: 17078124

Group type: EXPERIMENTAL
Intervention: Recruitment for treatment trial
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Participants assessed for the study
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Qualified participants who chose not to join
Number of subjects: 0
Study: 15499522

Group type: EXPERIMENTAL
Intervention: Patients with CRVO
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Patients with venous thrombosis
Number of subjects: 236

Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 236
Study: 12477521

Group type: EXPERIMENTAL
Intervention: Trial culture medium formulation
Number of subjects: 208

Group type: COMPARATOR
Intervention: Control culture medium formulation
Number of subjects: 208
Study: 9717115

Group type: EXPERIMENTAL
Intervention: Catheterization using a hysteroscopic catheter (3-French diameter tapering to 2 French at the tip)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (non-catheterized tubes)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Catheterization using a hysteroscopic catheter
Number of subjects: 20
Study: 7983951

Group type: EXPERIMENTAL
Intervention: Atrial pacing
Number of subjects: 225

Group type: COMPARATOR
Intervention: Ventricular pacing
Number of subjects: 225
Study: 3278115

Group type: EXPERIMENTAL
Intervention: Ultrasound localization
Number of subjects: 116

Group type: COMPARATOR
Intervention: Less than 10 needle manoeuvres
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: More than 10 needle manoeuvres
Number of subjects: 116
Study: 28983556

Group type: EXPERIMENTAL
Intervention: Ranibizumab, 0.5 mg, and verteporfin photodynamic therapy (vPDT)
Number of subjects: 322

Group type: COMPARATOR
Intervention: Ranibizumab, 0.5 mg, and sham PDT
Number of subjects: 322
Study: 26154207

Group type: EXPERIMENTAL
Intervention: 10 kg backpack
Number of subjects: 8
Study: 23803562

Group type: EXPERIMENTAL
Intervention: Acupressure wristbands (pressing the P6 point)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Sham acupressure wristbands
Number of subjects: 500

Group type: COMPARATOR
Intervention: Standard care only
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Acupressure wristbands (both real and sham)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Cost-effectiveness of acupressure
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Gender effect on nausea response
Number of subjects: 500
Study: 20653397

Group type: EXPERIMENTAL
Intervention: Diascorea alata (12 mg/sachet, 2 sachets daily for 12 months)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 19755462

Group type: EXPERIMENTAL
Intervention: Minimized extracorporeal circuits (Mini‐CPB)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional extracorporeal circuits (CECC)
Number of subjects: 40
Study: 16438813

Group type: EXPERIMENTAL
Intervention: Doctor received risk communication training alone
Number of subjects: 584

Group type: EXPERIMENTAL
Intervention: Doctor received SDM training alone
Number of subjects: 584

Group type: EXPERIMENTAL
Intervention: Doctor received both risk communication and SDM training
Number of subjects: 584

Group type: COMPARATOR
Intervention: Doctor received no training
Number of subjects: 584
Study: 15310009

Group type: EXPERIMENTAL
Intervention: AR CAG instability in BPH patients
Number of subjects: 84

Group type: COMPARATOR
Intervention: AR CAG and GGN repeat size
Number of subjects: 84
Study: 11545541

Group type: EXPERIMENTAL
Intervention: Capecitabine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: UFT/leucovorin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mayo Clinic regimen
Number of subjects: 0
Study: 9154286

Group type: EXPERIMENTAL
Intervention: Latanoprost (0.35, 115, and 350 micrograms/ml) administered topically to both eyes after a baseline day with vehicle (placebo).
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Latanoprost (10 times the clinically recommended dose for glaucoma treatment).
Number of subjects: 23

Group type: COMPARATOR
Intervention: Vehicle (placebo) administered to asthmatic patients on baseline day.
Number of subjects: 23
Study: 8330470

Group type: EXPERIMENTAL
Intervention: Torsemide (10 mg orally and intravenously)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Torsemide (10 mg)
Number of subjects: 12
Study: 3298087

Group type: EXPERIMENTAL
Intervention: Cefotetan
Number of subjects: 100

Group type: COMPARATOR
Intervention: Combination antibiotic therapy
Number of subjects: 100
Study: 29243965

Group type: EXPERIMENTAL
Intervention: Enasidenib monotherapy
Number of subjects: 0
Study: 26712605

Group type: EXPERIMENTAL
Intervention: ContEx (40 min of brisk walking 40 min after lunch)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: SplitEx (two 20‐min isoenergetic bouts, before and 40 min after meal)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control (standard lunch followed by normal daily activities)
Number of subjects: 9
Study: 25405014

Group type: EXPERIMENTAL
Intervention: 10-core biopsy protocol
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: 12-core biopsy protocol
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: 16-core biopsy protocol
Number of subjects: 354

Group type: COMPARATOR
Intervention: Comparison of 10-core, 12-core, and 16-core protocols
Number of subjects: 354
Study: 23274402

Group type: EXPERIMENTAL
Intervention: Kin Keeper(SM) Cancer Prevention Intervention (treatment group)
Number of subjects: 514

Group type: COMPARATOR
Intervention: Participant client group (control group)
Number of subjects: 514
Study: 19686327

Group type: EXPERIMENTAL
Intervention: Topical aloe vera (AV)
Number of subjects: 80

Group type: COMPARATOR
Intervention: 0.1% triamcinolone acetonide (TA)
Number of subjects: 80
Study: 18400727

Group type: EXPERIMENTAL
Intervention: Selenium supplementation (100 mug Se as sodium selenite/d) for 6 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Selenium withdrawal after supplementation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RNA-protein binding assays
Number of subjects: 0
Study: 16760808

Group type: EXPERIMENTAL
Intervention: Posteromedial approach
Number of subjects: 31

Group type: COMPARATOR
Intervention: Anterolateral approach
Number of subjects: 31
Study: 15223865

Group type: EXPERIMENTAL
Intervention: IL-8
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: ET-1
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: VEGF
Number of subjects: 49
Study: 11178853

Group type: EXPERIMENTAL
Intervention: Coumarin/troxerutine
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 9266098

Group type: EXPERIMENTAL
Intervention: Breast Conserving Therapy (BCT)
Number of subjects: 187

Group type: COMPARATOR
Intervention: Modified Radical Mastectomy (MRM)
Number of subjects: 187
Study: 8318241

Group type: EXPERIMENTAL
Intervention: Clonidine 150 micrograms IV over 30 minutes and an additional 150 micrograms during the following 90 minutes
Number of subjects: 60

Group type: COMPARATOR
Intervention: 0.9% sodium chloride IV at identical time intervals
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Clonidine infusion
Number of subjects: 60